Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc V.VIV.H

Alternate Symbol(s):  VIVXF

Healthcare
Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


TSXV:VIV.H - Post by User

Avivagen Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by hiker1on Feb 15, 2012 10:23pm
84 Views
Post# 19540900

RE: watch this video about chemaphor

RE: watch this video about chemaphor

You're turning out to be quite the DueD Pitbull there,  Ghost.......;0)~

One small correction though;  that video you just provided was completed prior to the decision by the company to terminate its licence with Vet-Stem.   This information was provided on Page 4 of the last release where it states, ...........

"Chemaphor recently announced that it has terminated its licence with Vet-Stem in order to expand the commerialization of its OxC-beta products and allocate more resources towards business development of OxC-beta from both a commerical and international context.  The termination of the Vet-Stem licence dramatically decreases Chemaphor's monthly burn, and allows for more optimal utilization of its resources and additional support towards business development activities."

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities